分阶段筛查识别具有神经元α-突触核蛋白病相关生物标志物的人群
研究评估了远程嗅觉测试分阶段筛查策略,用于富集多巴胺转运体单光子发射计算机断层成像(DAT-SPECT)异常和α-突触核蛋白聚集的个体。在60岁及以上未诊断帕金森病的参与者中,UPSIT低于第15百分位者DAT-SPECT结合率降低,且严重嗅觉减退者α-突触核蛋白种子扩增试验阳性率更高。
要点
- 远程UPSIT筛查可规模化招募疑似前驱期α-突触核蛋白病个体。
- UPSIT低于第10百分位者较第10至15百分位者DAT-SPECT低结合几率更高(OR 3.01)。
- UPSIT低于第15百分位且DAT-SPECT低结合者中55% aSynSAA阳性,严重嗅觉减退者达70%。
核心结论
- 远程嗅觉筛查联合DAT-SPECT低结合可识别高比例aSynSAA阳性的个体。
- 需纵向数据明确这些个体的进展模式,最终为疾病修饰临床试验招募提供依据。
研究设计与样本
- 帕金森进展标志物倡议(PPMI)前驱期队列招募60岁及以上、未诊断帕金森病的参与者。
- 参与者通过在线门户独立完成UPSIT,嗅觉减退者受邀完成DAT-SPECT,并进一步进行脑脊液α-突触核蛋白种子扩增试验(aSynSAA)。
主要发现
- 截至2024年1月29日,49,843人收到UPSIT,31,293人(63%)完成。
- 完成UPSIT者中8,301人(27%)得分低于第15百分位。
- 完成DAT-SPECT的1,546人中,1,060人(69%)DAT-SPECT结合低于年龄和性别预期值的100%。
- UPSIT低于第10百分位者(n=1,221)较第10至15百分位者DAT-SPECT低结合的几率更高(OR 3.01,95%CI 1.85-4.91)。
- UPSIT低于第15百分位且DAT-SPECT低于100%者中55%(198/363)aSynSAA阳性;严重嗅觉减退(UPSIT低于第10百分位)者中升至70%(182/260)。
局限性
- 需纵向数据明确这些个体的进展模式,原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Remote identification of individuals with severe hyposmia may enable scalable recruitment of participants with underlying alpha-synuclein aggregation. We evaluated the performance of a staged screening paradigm using remote smell testing to enrich for abnormal dopamine transporter single-photon emission computed tomography imaging (DAT-SPECT) and alpha-synuclein aggregation. METHODS: The Parkinson's Progression Markers Initiative (PPMI) recruited participants for the prodromal cohort who were 60-years and older without a Parkinson's disease diagnosis. Participants were invited to complete a University of Pennsylvania Smell Identification Test (UPSIT) independently through an online portal. Hyposmic participants were invited to complete DAT-SPECT, which determined eligibility for enrollment in longitudinal assessments and further biomarker evaluation including cerebrospinal fluid alpha-synuclein seed amplification assay (aSynSAA). RESULTS: As of January 29, 2024, 49,843 participants were sent an UPSIT and 31,293 (63%) completed it. Of UPSIT completers, 8,301 (27%) scored <15th percentile. Of 1,546 who completed DAT-SPECT, 1,060 (69%) had DAT-SPECT binding <100% expected for age and sex. Participants with an UPSIT <10th percentile (n = 1,221) had greater likelihood of low DAT-SPECT binding compared to participants with an UPSIT in the 10th to 15th percentile (odds ratio, 3.01; 95% confidence interval, 1.85-4.91). Overall, 55% (198/363) of cases with UPSIT <15th percentile and DAT-SPECT <100% had positive aSynSAA, which increased to 70% (182/260) when selecting for more severe hyposmia (UPSIT <10th percentile). INTERPRETATION: Remote screening for hyposmia and reduced DAT-SPECT binding identifies participants with a high proportion positive aSynSAA. Longitudinal data will be essential to define progression patterns in these individuals to ultimately inform recruitment into disease modification clinical trials. ANN NEUROL 2025;97:730-740.
引用
- Brown EG, Chahine LM, Siderowf A, et al. Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease. Ann Neurol. 2024. PMID: 39719857. doi:10.1002/ana.27158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。